KEYNOTE-B79 and IMMUNICY-1 clinical trials evaluating the Company’s allogeneic CAR T candidates, CYAD-101 and CYAD-211 respectively, expected to generate key data throughout 2022
Company’s proprietary non-gene edited shRNA technology clinically validated as a novel platform for the development of next-generation, allogeneic CAR Ts
Preclinical shRNA-based allogeneic pipeline continues to progress with IL-18-armored CAR T candidate CYAD-203 as well as discovery programs focused on in-licensed T-cell engagers targeting TAG72 and GPC3
Recent $32.5 million private placement with Fortress Investment Group affiliate to fund further research and development of Company’s current allogeneic CAR T pipeline
As of December 31, 2021, the Company ended the year with an unaudited treasury position of €30 million ($34 million)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.